Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUNICANCER
About this trial
This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).
Eligibility criteria
Qualifiers
Adult (over 18)
Treated (with radiotherapy or systemic anti-cancer treatment) for a lung cancer or diagnosed with metastatic lung cancer over the selection period at one of the participating site
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
UNICANCER
Lead sponsor
AstraZeneca
Collaborator
Merck Sharp & Dohme LLC
Collaborator
Roche Pharma AG
Collaborator
Pfizer
Collaborator
Bristol-Myers Squibb
Collaborator
Janssen, LP
Collaborator
Amgen
Collaborator
Daiichi Sankyo
Collaborator
Pierre Fabre Medicament
Collaborator
Boehringer Ingelheim
Collaborator
Source ClinicalTrials.gov